Shares of Zentalis Pharmaceuticals Inc. (ZNTL) are down more than 60% from their 52-week high of $31.46, recorded last May, and trade around $12.
The lead drug candidate is Azenosertib, a WEE1 inhibitor, in development for the treatment of cancer. Inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved WEE1 inhibitors. The company is also developing ZN-d5, a potent BCL-2 Inhibitor, as monotherapy and in combination with Azenosertib for the treatment of acute myeloid leukemia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com